Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Male Sexual Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Multicenter Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. SPEF2- And HYDIN-mutant cilia lack the central pair-associated protein SPEF2, aiding primary ciliary dyskinesia diagnostics

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Bronchiolitis obliterans (BO) following allogeneic haematopoietic SCT (HSCT) is a serious complication affecting 1.7-26% of the patients, with a reported mortality rate of 21-100%. It is considered a manifestation of chronic graft-versus-host disease, but our knowledge of aetiology and pathogenesis is still limited. Diagnostic criteria are being developed, and will allow more uniform and comparable research activities between centres. At present, no randomised controlled trials have been completed that could demonstrate an effective treatment. Steroids in combination with other immunosuppressive drugs still constitute the backbone of the treatment strategy, and results from our and other centres suggest that monthly infusions of high-dose pulse i.v. methylprednisolone (HDPM) might stabilise the disease and hinder progression. This article provides an overview of the current evidence regarding treatment options for BO and presents the treatment results with HDPM in a paediatric national HSCT-cohort.Bone Marrow Transplantation advance online publication, 29 August 2011; doi:10.1038/bmt.2011.161.
Original languageEnglish
JournalBone Marrow Transplantation
Volume47
Issue number8
Pages (from-to)1020-9
ISSN0268-3369
DOIs
Publication statusPublished - 2012

ID: 33226077